Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 09/01/22
End: 02/28/25
Due: 02/28/26
Phase: N/A
Priority: Normal
Start: 02/01/25
End: 08/01/26
Due: 08/01/27
Phase: N/A
Priority: Normal
Start: 05/05/23
End: 04/15/25
Due: 04/15/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC | NCT05533892 | Wan-Guang Zhang | user2@example.com | None | 2022-09-01 | 2025-02-28 | 2026-02-28 | - | - | 2025-07-14 |
| QL1706 As Second-line Treatment in Patients with Advanced Hepatocellular Carcinoma | NCT06822985 | Wan-Guang Zhang | user2@example.com | None | 2025-02-01 | 2026-08-01 | 2027-08-01 | - | - | 2025-07-14 |
| A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC | NCT05839197 | Wan-Guang Zhang | user2@example.com | None | 2023-05-05 | 2025-04-15 | 2026-04-15 | - | - | 2025-07-14 |